{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:57:56Z","timestamp":1781215076545,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.humpath.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T14:47:21Z","timestamp":1380120441000},"page":"2590-2596","source":"Crossref","is-referenced-by-count":22,"title":["Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization"],"prefix":"10.1016","volume":"44","author":[{"given":"Sung-Jig","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alegria","family":"Cantillep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2013.07.005_bb0005","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.humpath.2013.07.005_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the Her2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.humpath.2013.07.005_bb0015","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER2\/neu gene amplification and overexpression","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.humpath.2007.05.004","article-title":"Metallographic in situ hybridization","volume":"38","author":"Powell","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/PDM.0b013e31816f6374","article-title":"Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver enhanced (SISH) methods with patient outcome","volume":"18","author":"Francis","year":"2009","journal-title":"Diagn Mol Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/jcp.2009.062760","article-title":"Out of the darkness and into the light: bright field in situ hybridization for delineation of ERBB2 (HER2) status in breast carcinoma","volume":"63","author":"Gruver","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6890-12-3","article-title":"Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization","volume":"12","author":"Mollerup","year":"2012","journal-title":"BMC Clinical Pathology"},{"key":"10.1016\/j.humpath.2013.07.005_bb0045","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1365-2559.2011.04037.x","article-title":"Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing","volume":"59","author":"Hwang","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2013.07.005_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1746-1596-3-41","volume":"3","author":"Nitta","year":"2008","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/modpathol.2011.9","article-title":"Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer","volume":"24","author":"Koh","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4048\/jbc.2009.12.4.235","article-title":"Comparison of silver-enhanced in situ hybridization and fluorescent in situ hybridization for HER2 gene status in breast carcinomas","volume":"12","author":"Kang","year":"2009","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.humpath.2013.07.005_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00428-007-0424-5","article-title":"Comparison of automated silver enhanced in situ hybridization (SISH) for the validation of HER2 gene status in breast carcinoma according to the guideline of the American Society of Clinical Oncology and the College of American Pathologists","volume":"451","author":"Dietel","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2013.07.005_bb0070","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/modpathol.3800774","article-title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","volume":"20","author":"Dowsett","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/PDM.0b013e318064c72a","article-title":"Fluorescence in situ hybridization (FISH) as primary carcinoma of the breast","volume":"16","author":"Tubbs","year":"2007","journal-title":"Diagn Mol Pathol"},{"key":"10.1016\/j.humpath.2013.07.005_bb0080","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/jnci\/djm075","article-title":"Inconsistency of HER2 test raises questions","volume":"99","author":"Tuma","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2013.07.005_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3816\/CBC.2006.n.025","article-title":"Concordance between central and local laboratory HER2 testing from a community-based clinical study","volume":"7","author":"Reddy","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.humpath.2013.07.005_bb0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3816\/CBC.2005.n.026","article-title":"Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab","volume":"6","author":"Mass","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.humpath.2013.07.005_bb0095","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.humpath.2011.11.010","article-title":"Factors that impact turnaround time of surgical pathology specimens in an academic institution","volume":"43","author":"Patel","year":"2012","journal-title":"Hum Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771300292X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771300292X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T13:28:48Z","timestamp":1564061328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771300292X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S004681771300292X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2013.07.005","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}